ClinicalTrials.gg
RecruitingNCT06159101Updated Dec 6, 2023

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

A Phase 1 interventional study of HLX13 and CN-sourced ipilimumab in Healthy Male Volunteers, sponsored by Shanghai Henlius Biotech. Recruiting at 1 site in China. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects

Read the detailed description

This is a randomized, intravenous single-dose, parallel study to compare the PK characteristics of HLX13 and YERVOY® (US-, EU-, and CN-sourced) and evaluate their safety, tolerability, and immunogenicity in healthy Chinese male subjects.

This study is divided into two parts. Part I is an open-label, randomized, single-dose, parallel study to compare the PK parameters of HLX13 with those of EU-sourced YERVOY® in healthy Chinese male subjects after a single intravenous infusion and provide supporting data for the design of Part II. This part of the study consists of two groups.

Part II is a double-blind, randomized, single-dose, parallel study to evaluate the PK similarity of HLX 13 and YERVOY® (US-, EU-, and CN-sourced) in healthy Chinese male subjects. This part of the study consists of four groups.

02

Conditions studied

  • Healthy Male Volunteers

Keywords

  • CTLA-4
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign the form.
  2. Healthy Chinese males (no significant clinical abnormalities in medical history, physical examination, vital signs, chest X-ray, 12-lead , and laboratory examinations).
  3. Age ≥ 18 and ≤ 60 years old.
  4. (BMI) ≥ 18.5 and ≤ 28 kg/m2.
  5. (LVEF) > 50%, as measured by echocardiography within 14 days before randomization.
  6. Subjects either agree that they and their spouse/partner will take reliable measures within 3 months after the end of drug infusion or be infertile.

Exclusion criteria

Exclusion Criteria:

  1. History of any severe hematological or renal, endocrinic, respiratory, gastrointestinal, cardiovascular, hepatic, neuropsychiatric, or neurological diseases or tumors.
  2. Use of a monoclonal antibody or any biological product within 6 months prior to the study treatment.
  3. History of allergy or anaphylaxis, including that due to any drug or drug in clinical studies.
  4. Use of prescription/over-the-counter drugs or traditional Chinese medicines (except vitamins, mineral supplements, and health products) within 28 days prior to the study treatment.
  5. History of blood donation within 3 months prior to the study treatment.
  6. Participation in another clinical study and use of a clinical drug or reference product within 3 months prior to the study treatment, or planning to participate in another drug clinical trial during the study period.
  7. Positive for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or Treponema pallidum antibody.
  8. History of drug abuse, or positive urine drug screen during the screening period.
  9. Have undergone surgery within 3 months before screening or plan to undergo surgery during the study period; have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion.
  10. Have been vaccinated within 28 days prior to screening or plan to be vaccinated during the study.
  11. Intolerant to venipuncture or with a history of needle or blood phobia.
  12. People on special diets who reject the arranged meals.
  13. Smoking more than 5 cigarettes per day within 3 months before screening or cannot stop using any tobacco products during the study.
  14. An average daily alcohol intake of more than 15 g (equivalent to 450 mL beer or 150 mL wine or 50 mL low-alcohol liquor) within 1 month prior to screening; or a positive blood alcohol test at screening; or unwilling or unable to abstain from alcohol during the study.
  15. Failure to comply with protocol requirements and instructions, protocol restrictions, etc., as judged by the investigator; uncooperative or unable to return to the study site for follow-up visits or complete the entire clinical study process, etc.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (estimated)

Study arms

  • Experimental
    HLX13 group

    Recombinant anti-CTLA-4 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.

    Drug: HLX13

  • Active comparator
    CN-sourced ipilimumab group

    CN-sourced ipilimumab

    Drug: CN-sourced ipilimumab

  • Active comparator
    EU-sourced ipilimumab group

    EU-sourced ipilimumab

    Drug: EU-sourced ipilimumab group

  • Active comparator
    US-sourced ipilimumab group

    US-sourced ipilimumab

    Drug: US-sourced ipilimumab group

Interventions

  • DrugHLX13

    A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.

  • DrugCN-sourced ipilimumab

    A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.

  • A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.

  • A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  2. Maximum (peak) serum drug concentration (Cmax)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

Secondary outcomes

  1. Area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-t)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  2. Percentage of area under the serum concentration-time curve extrapolated to infinity (%AUCex)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  3. Time to reach maximum (peak) serum drug concentration (Tmax)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  4. Elimination half life (t1/2)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  5. Total clearance (CL)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  6. Apparent volume of distribution during terminal phase (Vz)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

  7. Mean residence time (MRT)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: Up to Day 90

Other outcomes

  1. Adverse events (AEs), serious adverse events (SAEs),

    Time frame: Up to Day 90

  2. Incidence of anti-drug antibodies (ADAs)

    Time frame: Up to Day 90

  3. Incidence of neutralizing antibodies (NAbs).

    Time frame: Up to Day 90

07

Study locations

1 of 1 sites recruiting
  • The Second Hospital of Anhui Medical University
    Anhui, Anhui, China
    Recruiting
    • Hu Wei · Contact+86-0551-65997165
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for May 2024, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Dec 6, 2023
StartActual
Nov 28, 2023
Primary completionEst.
May 28, 2024
CompletionEst.
May 28, 2024
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06159101
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Nov 28, 2023
Primary completion
May 28, 2024 (estimated)
Completion
May 28, 2024 (estimated)
Last update
Dec 6, 2023

Study contacts

Hu Wei
Contact
+86-0551-65997165
Hu Wei
principal investigator · The Second Hospital of Anhui Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX13

Start the discussion